AI drug startup considers public offering
The company, based in Baltimore, utilizes machine learning to expedite the drug discovery process. Insilico's AI-based platform has been employed by pharmaceutical companies like Pfizer. The decision to go public comes after the company raised $255 million in a funding round. The company's valuation has soared due to the increasing importance of AI in medical research.
About the Company
The company, based in Baltimore, utilizes machine learning to expedite the drug discovery process. Insilico's AI-based platform has been employed by pharmaceutical companies like Pfizer.
Company's Recent Decision
The decision to go public comes after the company raised $255 million in a funding round.
Valuation of the Company
The company's valuation has soared due to the increasing importance of AI in medical research.